Therabron

About Therabron

Therabron Therapeutics is a clinical-stage biopharmaceutical company focused on developing a new class of drugs for respiratory conditions. The company's research is based on the secretoglobin family of proteins, a naturally occurring family of proteins with potential therapeutic applications.

Therabron's lead product candidate, Therabron™, is a recombinant human club cell secretory protein being developed for the treatment of respiratory diseases. The company is also advancing other therapeutic proteins to address a variety of neglected and undertreated respiratory conditions. Therabron Therapeutics is actively engaged in clinical trials to evaluate the safety and efficacy of its product candidates. The company's primary focus is on the development of treatments for inflammatory and fibrotic lung diseases.

Therabron Therapeutics operates in the biotechnology and pharmaceutical markets. The company's business model is centered on the research, development, and commercialization of its proprietary drug candidates. As a clinical-stage company, its revenue generation will be dependent on the successful completion of clinical trials and regulatory approval of its products.